Institution
Casa Sollievo della Sofferenza
Healthcare•San Giovanni Rotondo, Italy•
About: Casa Sollievo della Sofferenza is a healthcare organization based out in San Giovanni Rotondo, Italy. It is known for research contribution in the topics: Population & Cancer. The organization has 2234 authors who have published 6183 publications receiving 239811 citations. The organization is also known as: Home for Relief of the Suffering.
Topics: Population, Cancer, Gene, Diabetes mellitus, Type 2 diabetes
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The phenotype of HUCB CD34+ cells is quite heterogeneous and contains subpopulations of both early and committed hematopoietic progenitors which may represent a valid source for transplantation.
Abstract: BACKGROUND: Human umbilical cord blood (HUCB) is a possible alternative to bone marrow (BM) and mobilized peripheral blood (PB) for transplantation of hematopoietic progenitors. The aim of this study was to evaluate the phenotypic profile of CD34+ progenitors present in HUCB. MATERIALS AND METHODS: A flow cytometric analysis was performed on 20 HUCB samples, using a large panel of monoclonal antibodies recognizing different lineage or activation antigens, in double labeling with CD34. RESULTS: A toal of 13,897 +/- 2,529 cells/microL, 0.84 +/- 0.83% of which were CD34+, was found. The large majority of CD34+ cells were committed toward initial myeloid differentiation (CD33+, CD13+) and expressed the transferrin receptor (CD71). A substantial proportion of these cells (about 40%) co-expressed CD45RA and CD117, while a very small number displayed markers of advanced myeloid commitment, such as CD14, CD15 and CD41 (less than 2%), or those of lymphoid differentiation: CD2, CD5, CD7, CD10 and CD19 (less than 6%). About 11% of HUCB CD34+ cells were primitive progenitors, as suggested by the absence of HLA-DR and CD38 on their surface. CONCLUSIONS: As previously observed in BM and mobilized PB, the phenotype of HUCB CD34+ cells is quite heterogeneous. In particular, HUCB contains subpopulations of both early and committed hematopoietic progenitors which may represent a valid source for transplantation.
69 citations
••
TL;DR: Three cases of congenital absence of an internal carotid artery (ICA) are reported, diagnosed incidentally by digital subtraction angiography, based on the classification of segmental ICA agenesis proposed by Lasjaunias and Berenstein.
Abstract: We report three cases of congenital absence of an internal carotid artery (ICA), diagnosed incidentally by digital subtraction angiography. The analysis of the cases is based on the classification of segmental ICA agenesis proposed by Lasjaunias and Berenstein. Usually the patients with this rare vascular anomaly are asymptomatic; some may have symptoms related to cerebrovascular insufficiency, compression by enlarged intracranial collateral vessels, or complications associated with cerebral aneurysms. Diagnosis of congenital absence of ICA is made by skull base computed tomography (CT) scan, CT and magnetic resonance angiography, and conventional or digital subtraction angiography.
69 citations
••
TL;DR: A new mechanism by which drug-induced senescence is epigenetically regulated by macroH2A1 and DNA methylation is revealed and suggested as a novel biomarker of hepatic senescences that could potentially predict prognosis and disease progression is suggested.
Abstract: Aging is a major risk factor for progression of liver diseases to hepatocellular carcinoma (HCC). Cellular senescence contributes to age-related tissue dysfunction, but the epigenetic basis underlying drug-induced senescence remains unclear. macroH2A1, a variant of histone H2A, is a marker of senescence-associated heterochromatic foci that synergizes with DNA methylation to silence tumor-suppressor genes in human fibroblasts. In this study, we investigated the relationship between macroH2A1 splice variants, macroH2A1.1 and macroH2A1.2, and liver carcinogenesis. We found that protein levels of both macroH2A1 isoforms were increased in the livers of very elderly rodents and humans, and were robust immunohistochemical markers of human cirrhosis and HCC. In response to the chemotherapeutic and DNA-demethylating agent 5-aza-deoxycytidine (5-aza-dC), transgenic expression of macroH2A1 isoforms in HCC cell lines prevented the emergence of a senescent-like phenotype and induced synergistic global DNA hypomethylation. Conversely, macroH2A1 depletion amplified the antiproliferative effects of 5-aza-dC in HCC cells, but failed to enhance senescence. Senescence-associated secretory phenotype and whole-transcriptome analyses implicated the p38 MAPK/IL8 pathway in mediating macroH2A1-dependent escape of HCC cells from chemotherapy-induced senescence. Furthermore, chromatin immunoprecipitation sequencing revealed that this hepatic antisenescence state also required active transcription that could not be attributed to genomic occupancy of these histones. Collectively, our findings reveal a new mechanism by which drug-induced senescence is epigenetically regulated by macroH2A1 and DNA methylation and suggest macroH2A1 as a novel biomarker of hepatic senescence that could potentially predict prognosis and disease progression.
69 citations
••
University of Modena and Reggio Emilia1, University of Pavia2, Catholic University of the Sacred Heart3, University of Eastern Piedmont4, Academy for Urban School Leadership5, University of Chieti-Pescara6, Vita-Salute San Raffaele University7, University of Naples Federico II8, University of Insubria9, University of Catania10, University of Milan11, University of Padua12, Casa Sollievo della Sofferenza13, University of Pisa14, University of Florence15, University of Milano-Bicocca16, University of Palermo17, Magna Græcia University18, University of Molise19, Aarhus University Hospital20, Boston University21
TL;DR: In this article, the authors evaluated if in-hospital administration of heparin improved survival in a large cohort of Italian COVID-19 patients, and they found a 40% lower risk of death in patients receiving hecarin (hazard ratio 0.60; 95% confidence interval: 0.49-0.74; E-value 2.04).
Abstract: Introduction A hypercoagulable condition was described in patients with coronavirus disease 2019 (COVID-19) and proposed as a possible pathogenic mechanism contributing to disease progression and lethality. Aim We evaluated if in-hospital administration of heparin improved survival in a large cohort of Italian COVID-19 patients. Methods In a retrospective observational study, 2,574 unselected patients hospitalized in 30 clinical centers in Italy from February 19, 2020 to June 5, 2020 with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 infection were analyzed. The primary endpoint in a time-to event analysis was in-hospital death, comparing patients who received heparin (low-molecular-weight heparin [LMWH] or unfractionated heparin [UFH]) with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse probability for treatment weighting by propensity scores. Results Out of 2,574 COVID-19 patients, 70.1% received heparin. LMWH was largely the most used formulation (99.5%). Death rates for patients receiving heparin or not were 7.4 and 14.0 per 1,000 person-days, respectively. After adjustment for propensity scores, we found a 40% lower risk of death in patients receiving heparin (hazard ratio = 0.60; 95% confidence interval: 0.49–0.74; E-value = 2.04). This association was particularly evident in patients with a higher severity of disease or strong coagulation activation. Conclusion In-hospital heparin treatment was associated with a lower mortality, particularly in severely ill COVID-19 patients and in those with strong coagulation activation. The results from randomized clinical trials are eagerly awaited to provide clear-cut recommendations.
69 citations
••
TL;DR: Mutations in the epsilon-sarcoglycan gene (SGCE) are found in six (21%) of the 29 patients with essential myoclonus and myoclonic dystonia, but the full spectrum of the phenotype may not be fully defined.
Abstract: Mutations in the epsilon-sarcoglycan gene (SGCE) are associated with familial myoclonus dystonia, but the full spectrum of the phenotype may not be fully defined. We screened 58 individuals with a range of myoclonic/dystonic syndromes for SGCE mutations. We found mutations (four of them novel) in six (21%) of the 29 patients with essential myoclonus and myoclonic dystonia, but did not find mutations in the 29 patients with other phenotypes.
69 citations
Authors
Showing all 2237 results
Name | H-index | Papers | Citations |
---|---|---|---|
Ralph B. D'Agostino | 226 | 1287 | 229636 |
Cisca Wijmenga | 136 | 668 | 86572 |
Massimo Mangino | 116 | 369 | 84902 |
Xavier Estivill | 110 | 673 | 59568 |
Andrea Natale | 106 | 945 | 52520 |
Stefano Pileri | 100 | 635 | 43369 |
Bruno Dallapiccola | 94 | 935 | 43208 |
Fortunato Ciardiello | 94 | 695 | 47352 |
F. Bianchi | 91 | 1370 | 40011 |
Paolo Gasparini | 91 | 431 | 36059 |
Joseph G. Gleeson | 86 | 307 | 23345 |
Mario Rizzetto | 79 | 470 | 33693 |
Giuseppe Leone | 74 | 654 | 21451 |
Maurizio Pompili | 74 | 783 | 20649 |
Massimo Rugge | 74 | 594 | 25624 |